glp-1 agonists thyroid cancer Glucagon-like peptide 1 receptor agonist use and risk of cancer: Scandinavian cohort study Glucagon-like peptide 1 receptor agonists

Zhang L, Zhang L, Li L, Holscher C

GLP-1 specifically binds to the glucagon-like peptide-1 receptor (GLP-1R) in the body, directly stimulating the secretion of insulin by pancreatic -cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycemic lowering effect

10.1210/jc.2009-0921 34 Hauge-EvansA

Children 12 or older can take it if they are at or above the 95th weight percentile for their sex and age

First lets take a look into what the journey of someone that takes the medication might look like What most clearly distinguishes GLP-1 users is the change in their daily habits once they are on treatment

If additional glycemic improvement is needed, increase by 2.5-mg increments after at least 4 weeks at current dose